DUALISTIC EFFECTS OF CIS-DIAMMINE-DICHLORO-PLATINUM ON THE ANTITUMOR EFFICACY OF SUBSEQUENTLY APPLIED RECOMBINANT INTERLEUKIN-2 THERAPY - A TUMOR-DEPENDENT PHENOMENON

被引:7
作者
BERNSEN, MR [1 ]
VANBARLINGEN, HJJ [1 ]
VANDERVELDEN, AW [1 ]
DULLENS, HFJ [1 ]
DENOTTER, W [1 ]
HEINTZ, APM [1 ]
机构
[1] UNIV HOSP UTRECHT,DEPT OBSTET & GYNECOL,3508 GA UTRECHT,NETHERLANDS
关键词
D O I
10.1002/ijc.2910540326
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The efficacy with which disseminated SL2 and P815 tumors, in syngeneic DBA/2 mice, can be eradicated with low-dose recombinant interleukin-2 (rIL-2) therapy is about equal. Treatment (i.p.) of DBA/2 mice, injected i.p. with SL2 or P81 5 cells on day 0, with rIL-2 (Proleukin) on days 10 to 14 results in a cure rate of 50 to 60% in each case. The in vitro sensitivity of SL2 and P815 cells to cis-diammine-dichloro-platinum [11] (cisplatin) is also comparable, although P815 appears to be slightly more sensitive. In vivo, however, therapy with cisplatin is far less effective against P815 than against SL2. In the DBA/2-SL2 model, at all doses tested, combination therapy with cisplatin (administered on day 2) and rIL-2 (administered on days 10-14) resulted in anti-tumor efficacy greater than that of either drug separately. In contrast, in the DBA/2-P815 model, cisplatin decreased the anti-tumor efficacy of subsequently applied rIL-2 therapy. As the only difference between the 2 tumor models is the. tumor itself, the success of combination therapy with cisplatin and rIL-2 was dependent on tumor characteristics. We suggest that in these 2 tumor models, neither the sensitivity of these tumors to cisplatin nor their growth and dissemination patterns were responsible for the contrasting results of combination therapy in these models. Instead, tumor-dependent immune-modulating effects of cisplatin may be the cause of these effects. These immune-modulating effects may comprise (a) effects of cisplatin on the tumor cells, resulting in changes in their susceptibility to immune effector cells, or changes in their immunogenicity; (b) activating or suppressive effects of cisplatin on immune effector cells; or (c) a combination of these effects. These effects could then either synergize or antagonize with the immune activating properties of rIL-2.
引用
收藏
页码:513 / 517
页数:5
相关论文
共 19 条
[11]  
MUGGIA FM, 1989, SEMIN ONCOL, V16, P123
[12]  
MUGGIA FM, 1991, SEMIN ONCOL, V18, P1
[13]   INVITRO ANALYSIS OF THE ANTICANCER POTENTIAL OF TUMOR NECROSIS FACTOR IN COMBINATION WITH CISPLATIN [J].
MUTCH, DG ;
POWELL, CB ;
KAO, MS ;
COLLINS, JL .
GYNECOLOGIC ONCOLOGY, 1989, 34 (03) :328-333
[14]  
PAPA MZ, 1988, CANCER RES, V48, P122
[15]   CISPLATIN (CIS-DIAMMINEDICHLOROPLATINUM-II) [J].
PRESTAYKO, AW ;
DAOUST, JC ;
ISSELL, BF ;
CROOKE, ST .
CANCER TREATMENT REVIEWS, 1979, 6 (01) :17-39
[16]  
ROSENBERG B, 1975, CANCER CHEMOTH REP 1, V59, P589
[17]  
SCHEPER RJ, 1987, METHOD FIND EXP CLIN, V9, P611
[18]   INTERLEUKIN-2 - INCEPTION, IMPACT, AND IMPLICATIONS [J].
SMITH, KA .
SCIENCE, 1988, 240 (4856) :1169-1176
[19]   ACTIVATION OF HUMAN NK CELLS AND MONOCYTES WITH CISPLATIN INVITRO [J].
SODHI, A ;
PAI, K ;
SINGH, RK ;
SINGH, SM .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1990, 12 (08) :893-898